In summary, TGFβ can thus be seen as a relevant antagonist of the immunological control of CRC disease, both by limiting the presence of cytolytic effector immune cells in the tumor and by promoting the T cell-mediated secretion of pro-tumorigenic cytokines. This evidence concerns the gene TGFB1 and colorectal carcinoma.